[
  {
    "patient_id": "PATIENT_5B8128A6",
    "drug": "Codeine",
    "timestamp": "2026-02-19T16:51:46.705186",
    "risk_assessment": {
      "risk_label": "Ineffective",
      "confidence_score": 0.95,
      "severity": "high"
    },
    "cpic_guidelines": {
      "recommendation_level": "1A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "Poor metabolizers have little-to-no morphine formation, making codeine ineffective for pain relief.",
      "cpic_evidence": "1A - Strong",
      "reference": "PharmGKB CPIC Codeine/CYP2D6"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*2/*2",
      "phenotype": "PM",
      "detected_variants": [
        {
          "rsid": "rs7364978",
          "gene": "CYP2D6",
          "genotype": "*2/*2",
          "phenotype": "Poor Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "NOT RECOMMENDED for pain control - Use alternative analgesic (morphine, oxycodone, hydromorphone, tramadol, or non-opioid options)",
      "dosing": "0% - Do not use% adjustment",
      "monitoring": "If used despite recommendation: Monitor for complete lack of pain relief"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Codeine shows ineffective risk.",
      "clinical_impact": "CYP2D6 (Poor Metabolizer): Ineffective"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6"
      ],
      "variant_count": 1,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  },
  {
    "patient_id": "PATIENT_5B8128A6",
    "drug": "Tramadol",
    "timestamp": "2026-02-19T16:51:46.705186",
    "risk_assessment": {
      "risk_label": "Unknown",
      "confidence_score": 0.5,
      "severity": "none"
    },
    "cpic_guidelines": {
      "recommendation_level": "No data",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "",
      "cpic_evidence": "No data",
      "reference": "Manual review required"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*2/*2",
      "phenotype": "PM",
      "detected_variants": [
        {
          "rsid": "rs7364978",
          "gene": "CYP2D6",
          "genotype": "*2/*2",
          "phenotype": "Poor Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Consult with clinical pharmacist or pharmacogenomic specialist",
      "dosing": "Unknown% adjustment",
      "monitoring": "Standard monitoring"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Tramadol shows unknown risk.",
      "clinical_impact": "No pharmacogenomic data available for 'Tramadol'. Consult clinical pharmacist or CPIC guidelines."
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6"
      ],
      "variant_count": 1,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  },
  {
    "patient_id": "PATIENT_5B8128A6",
    "drug": "Metoprolol",
    "timestamp": "2026-02-19T16:51:46.705186",
    "risk_assessment": {
      "risk_label": "Unknown",
      "confidence_score": 0.5,
      "severity": "none"
    },
    "cpic_guidelines": {
      "recommendation_level": "2B",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "Poor metabolizers may accumulate metoprolol; increased side effects.",
      "cpic_evidence": "2B - Moderate",
      "reference": "PharmGKB CYP2D6 Metabolizers"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*2/*2",
      "phenotype": "PM",
      "detected_variants": [
        {
          "rsid": "rs7364978",
          "gene": "CYP2D6",
          "genotype": "*2/*2",
          "phenotype": "Poor Metabolizer"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce dose 25-50%; consider alternative beta-blocker not metabolized by CYP2D6 (atenolol, bisoprolol, carvedilol)",
      "dosing": "50-75% reduction% adjustment",
      "monitoring": "Monitor for bradycardia (< 50 bpm), hypotension, fatigue, dizziness"
    },
    "llm_generated_explanation": {
      "summary": "Based on genetic profile, Metoprolol shows unknown risk.",
      "clinical_impact": "CYP2D6: No CPIC mapping for Metoprolol - manual review recommended"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": [
        "CYP2D6"
      ],
      "variant_count": 1,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2"
    }
  }
]